Homebased Medication Review: evaluation of homebased medication review by community pharmacists in elderly people: a randomised controlled trial

ISRCTN ISRCTN03155973
DOI https://doi.org/10.1186/ISRCTN03155973
Secondary identifying numbers NTR1036
Submission date
05/09/2007
Registration date
05/09/2007
Last edited
17/09/2008
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr A. Faber
Scientific

SIR Institute for Pharmacy Practice and Policy
Leiden
2331 JE
Netherlands

Phone +31 (0)71 576 6157
Email a.faber@stevenshof.nl

Study information

Study designMulticentre, randomised, placebo-controlled, parallel group trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)GP practice
Study typeQuality of life
Scientific title
Study objectivesAn home-based medication review intervention conducted by a community pharmacists in close collaboration with the General Practitioner (GP) and patient improves the quality of pharmacotherapy in elderly patients.
Ethics approval(s)Ethics approval received from the Medical Ethics Board of UMC Utrecht (University Medical Centre in Utrecht) (The Netherlands) on the 7th August 2007 (ref: 07-120/E; CCMO no.: 16412.041.07).
Health condition(s) or problem(s) studiedHome-based medication review
InterventionA medication review will be performed by the patient’s pharmacist, using the medication list and GP clinical records. The medication review is evaluated and, if necessary, completed by an independent pharmacist panel. All potential drug related problems are identified and classified. The pharmacist visits the patient at home for an interview about the patient's medicines and to identify other possible drug related problems. The medication review will be completed using the information from the patient's interview. Adjustments in pharmacotherapy will be proposed and discussed with the patient’s GP. A treatment plan will be formulated. The GP or pharmacist will discuss the treatment plan with the patient.

Patients in the control group receive regular care.
Intervention typeOther
Primary outcome measure1. The number of drug related problems per patient
2. The number of patients achieving target levels concerning blood pressure, cholesterol and HbA1C

Outcomes will be measured at baseline (t = 0), and after 6 and 12 months after the intervention.
Secondary outcome measures1. The number of patient being treated optimally according to clinical guidelines
2. The number of medicines per patient
3. The number unplanned hospital admissions
4. Change in mean values for HBA1C, cholesterol level and/or blood pressure
5. Quality of life
6. Satisfaction of GPs, pharmacists and patient with the intervention
7. The capability of pharmacists to perform a comprehensive medication review

Outcomes will be measured at baseline (t = 0), and after 6 and 12 months after the intervention.
Overall study start date01/09/2007
Completion date01/09/2009

Eligibility

Participant type(s)Patient
Age groupSenior
SexBoth
Target number of participants400
Key inclusion criteria1. Persons aged 65 years or older
2. Prescribed five or more regular medicines, including at least one cardiovascular or anti-diabetic drug
Key exclusion criteriaPersons receiving repeat prescriptions solely from a specialist.
Date of first enrolment01/09/2007
Date of final enrolment01/09/2009

Locations

Countries of recruitment

  • Netherlands

Study participating centre

SIR Institute for Pharmacy Practice and Policy
Leiden
2331 JE
Netherlands

Sponsor information

Lloyds Apotheken (The Netherlands)
Industry

Postbus 191
Baarn
3740 AD
Netherlands

Email info@lloydsapotheken.nl
Website http://www.lloydsapotheken.nl/
ROR logo "ROR" https://ror.org/04ph6g561

Funders

Funder type

Industry

AstraZeneca (The Netherlands)
Government organisation / For-profit companies (industry)
Alternative name(s)
AstraZeneca PLC, Pearl Therapeutics
Location
United Kingdom
Menzis Healthcare Insurance (Menzis Zorgverzekeraar) (The Netherlands)

No information available

Lloyds Apotheken (The Netherlands)

No information available

Achmea (The Netherlands)

No information available

Royal Dutch Pharmaceutical Society (Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie [KNMP]) (The Netherlands)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan